We have developed an artificial intelligence platform to design antimicrobial peptides for treatment of antimicrobial resistant pathogens, including the notoriously difficult to treat mycobacterium abscessus. We plan to use the funding to achieve three goals: Validate our findings in vivo; expand the current indications of our lead assets; and complete Investigational New Drug-enabling studies.